Altamira Therapeutics Ltd. Current Service Cost Net Defined Benefit Liability Asset
Altamira Therapeutics Ltd. (CYTOF) reported Current Service Cost Net Defined Benefit Liability Asset of $200.00 thousand for the 12-month period ending 2024-12-31, per its 20-F filed 2025-04-30.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:CurrentServiceCostNetDefinedBenefitLiabilityAsset · last filed 2025-04-30
CHF
| Period end | Current Service Cost Net Defined Benefit Liability Asset 12 month |
|---|---|
| 2023-12-31 | 163.10K CHF 20-F/A · filed 2024-04-22 |
| 2022-12-31 | 256.34K CHF 20-F/A · filed 2024-04-22 |
| 2021-12-31 | 159.09K CHF 20-F/A · filed 2024-04-22 |
| 2020-12-31 | 151.62K CHF 20-F · filed 2023-05-16 |
| 2019-12-31 | 138.58K CHF 20-F · filed 2022-04-12 |
| 2018-12-31 | 90.16K CHF 20-F · filed 2021-03-31 |
| 2017-12-31 | 348.17K CHF 20-F · filed 2020-04-16 |
| 2016-12-31 | 319.17K CHF 20-F · filed 2019-03-14 |
| 2015-12-31 | 261.78K CHF 20-F · filed 2018-03-22 |
USD
| Period end | Current Service Cost Net Defined Benefit Liability Asset 12 month |
|---|---|
| 2024-12-31 | $200.00K 20-F · filed 2025-04-30 |
| 2023-12-31 | $181.53K 20-F · filed 2025-04-30 |
| 2022-12-31 | $268.42K 20-F · filed 2025-04-30 |